Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Legend Biotech
Pharma
Merck-Curon, Legend, Amgen—Fierce Pharma Asia
Merck licensed a bispecific from Curon. Legend is taking a close look at its business. The FDA flagged missing adverse events in an Amgen filing.
Angus Liu
Aug 16, 2024 8:59am
Legend CEO talks BIOSECURE Act, M&A rumor and Carvykti growth
Aug 9, 2024 10:30am
Hengrui, Sanofi and Aslan—Fierce Pharma Asia
Jul 19, 2024 9:48am
J&J partner Legend Biotech reportedly receives buyout offer
Jul 15, 2024 11:06am
Eisai, Takeda, BIOSECURE—Fierce Pharma Asia
Jul 12, 2024 9:05am
J&J, Legend's Carvykti extends lives in multiple myeloma trial
Jul 2, 2024 9:58am
